Explainable machine learning on baseline MRI predicts multiple sclerosis trajectory descriptors.

Journal: PloS one
PMID:

Abstract

Multiple sclerosis (MS) is a multifaceted neurological condition characterized by challenges in timely diagnosis and personalized patient management. The application of Artificial Intelligence (AI) to MS holds promises for early detection, accurate diagnosis, and predictive modeling. The objectives of this study are: 1) to propose new MS trajectory descriptors that could be employed in Machine Learning (ML) regressors and classifiers to predict patient evolution; 2) to explore the contribution of ML models in discerning MS trajectory descriptors using only baseline Magnetic Resonance Imaging (MRI) studies. This study involved 446 MS patients who had a baseline MRI, at least two measurements of Expanded Disability Status Scale (EDSS), and a 1-year follow-up. Patients were divided into two groups: 1) for model development and 2) for evaluation. Three descriptors: β1, β2, and EDSS(t), were related to baseline MRI parameters using regression and classification XGBoost models. Shapley Additive Explanations (SHAP) analysis enhanced model transparency by identifying influential features. The results of this study demonstrate the potential of AI in predicting MS progression using the proposed patient trajectories and baseline MRI scans, outperforming classic Multiple Linear Regression (MLR) methods. In conclusion, MS trajectory descriptors are crucial; incorporating AI analysis into MRI assessments presents promising opportunities to advance predictive capabilities. SHAP analysis enhances model interpretation, revealing feature importance for clinical decisions.

Authors

  • Silvia Campanioni
    Galicia Sur Health Research Institute (IIS Galicia Sur), Álvaro Cunqueiro Hospital, 36310 Vigo, Spain.
  • César Veiga
    Galicia Sur Health Research Institute (IIS Galicia Sur), Álvaro Cunqueiro Hospital, 36310 Vigo, Spain.
  • José María Prieto-González
    Health Research Institute of Santiago de Compostela (IDIS), Translational Research in Neurological Diseases Group, Santiago University Hospital Complex, SERGAS-USC, Santiago de Compostela, Spain.
  • José A González-Nóvoa
    Galicia Sur Health Research Institute (IIS Galicia Sur), Álvaro Cunqueiro Hospital, 36310 Vigo, Spain.
  • Laura Busto
    Galicia Sur Health Research Institute (IIS Galicia Sur), Álvaro Cunqueiro Hospital, 36310 Vigo, Spain.
  • Carlos Martinez
    Galicia Sur Health Research Institute (IIS Galicia Sur), Cardiovascular Research Group, Vigo, Spain.
  • Miguel Alberte-Woodward
    Health Research Institute of Santiago de Compostela (IDIS), Translational Research in Neurological Diseases Group, Santiago University Hospital Complex, SERGAS-USC, Santiago de Compostela, Spain.
  • Jesús García de Soto
    Health Research Institute of Santiago de Compostela (IDIS), Translational Research in Neurological Diseases Group, Santiago University Hospital Complex, SERGAS-USC, Santiago de Compostela, Spain.
  • Jessica Pouso-Diz
    Health Research Institute of Santiago de Compostela (IDIS), Translational Research in Neurological Diseases Group, Santiago University Hospital Complex, SERGAS-USC, Santiago de Compostela, Spain.
  • María de Los Ángeles Fernández Ceballos
    Health Research Institute of Santiago de Compostela (IDIS), Translational Research in Neurological Diseases Group, Santiago University Hospital Complex, SERGAS-USC, Santiago de Compostela, Spain.
  • Roberto Carlos Agis-Balboa
    Health Research Institute of Santiago de Compostela (IDIS), Translational Research in Neurological Diseases Group, Santiago University Hospital Complex, SERGAS-USC, Santiago de Compostela, Spain.